English
简体中文
Total: £ 56.28
Published Date: 2026-03-20 | Pages: 116 | Tables: 112 | Pharma & Healthcare
The global Biologics for Severe Asthma market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Biologics for Severe Asthma competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Biologics for severe asthma are a class of drugs used to treat severe asthma. These drugs mainly work by regulating the immune system to reduce inflammation and control asthma symptoms.
The North American market for Biologics for Severe Asthma is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Biologics for Severe Asthma is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Biologics for Severe Asthma include AstraZeneca, Amgen, Roche, Novartis, Sanofi, Regeneron Pharmaceuticals, GSK, Teva Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Biologics for Severe Asthma market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Biologics for Severe Asthma. The Biologics for Severe Asthma market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Biologics for Severe Asthma market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Biologics for Severe Asthma manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
AstraZeneca
Amgen
Roche
Novartis
Sanofi
Regeneron Pharmaceuticals
GSK
Teva Pharmaceuticals
Segment by Type
Omalizumab
Benralizumab
Dupirumab
Mepolizumab
Reslizumab
Tezepelumab-ekko
by Application
Hospital
Clinic
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Biologics for Severe Asthma manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Biologics for Severe Asthma sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Biologics for Severe Asthma Market Overview
1.1 Product Definition
1.2 Biologics for Severe Asthma by Type
1.2.1 Global Biologics for Severe Asthma Market Value by Type: 2025 vs 2032
1.2.2 Omalizumab
1.2.3 Benralizumab
1.2.4 Dupirumab
1.2.5 Mepolizumab
1.2.6 Reslizumab
1.2.7 Tezepelumab-ekko
1.3 Biologics for Severe Asthma by Application
1.3.1 Global Biologics for Severe Asthma Market Value by Application: 2025 vs 2032
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Biologics for Severe Asthma Market Size Estimates and Forecasts
1.4.1 Global Biologics for Severe Asthma Revenue 2021–2032
1.4.2 Global Biologics for Severe Asthma Sales 2021–2032
1.4.3 Global Biologics for Severe Asthma Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Biologics for Severe Asthma Market Competition by Manufacturers
2.1 Global Biologics for Severe Asthma Sales Market Share by Manufacturers (2021–2026)
2.2 Global Biologics for Severe Asthma Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Biologics for Severe Asthma Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Biologics for Severe Asthma, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Biologics for Severe Asthma, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Biologics for Severe Asthma, Product Types and Applications
2.7 Global Key Manufacturers of Biologics for Severe Asthma, Date of Entry into the Industry
2.8 Global Biologics for Severe Asthma Market Competitive Situation and Trends
2.8.1 Global Biologics for Severe Asthma Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Biologics for Severe Asthma Players Market Share by Revenue
2.8.3 Global Biologics for Severe Asthma Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Biologics for Severe Asthma Market Scenario by Region
3.1 Global Biologics for Severe Asthma Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Biologics for Severe Asthma Sales by Region: 2021–2032
3.2.1 Global Biologics for Severe Asthma Sales by Region: 2021–2026
3.2.2 Global Biologics for Severe Asthma Sales by Region: 2027–2032
3.3 Global Biologics for Severe Asthma Revenue by Region: 2021–2032
3.3.1 Global Biologics for Severe Asthma Revenue by Region: 2021–2026
3.3.2 Global Biologics for Severe Asthma Revenue by Region: 2027–2032
3.4 North America Biologics for Severe Asthma Market Facts & Figures by Country
3.4.1 North America Biologics for Severe Asthma Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Biologics for Severe Asthma Sales by Country (2021–2032)
3.4.3 North America Biologics for Severe Asthma Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Biologics for Severe Asthma Market Facts & Figures by Country
3.5.1 Europe Biologics for Severe Asthma Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Biologics for Severe Asthma Sales by Country (2021–2032)
3.5.3 Europe Biologics for Severe Asthma Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Biologics for Severe Asthma Market Facts & Figures by Region
3.6.1 Asia Pacific Biologics for Severe Asthma Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Biologics for Severe Asthma Sales by Region (2021–2032)
3.6.3 Asia Pacific Biologics for Severe Asthma Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Biologics for Severe Asthma Market Facts & Figures by Country
3.7.1 Latin America Biologics for Severe Asthma Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Biologics for Severe Asthma Sales by Country (2021–2032)
3.7.3 Latin America Biologics for Severe Asthma Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Biologics for Severe Asthma Market Facts & Figures by Country
3.8.1 Middle East and Africa Biologics for Severe Asthma Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Biologics for Severe Asthma Sales by Country (2021–2032)
3.8.3 Middle East and Africa Biologics for Severe Asthma Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Biologics for Severe Asthma Sales by Type (2021–2032)
4.1.1 Global Biologics for Severe Asthma Sales by Type (2021–2026)
4.1.2 Global Biologics for Severe Asthma Sales by Type (2027–2032)
4.1.3 Global Biologics for Severe Asthma Sales Market Share by Type (2021–2032)
4.2 Global Biologics for Severe Asthma Revenue by Type (2021–2032)
4.2.1 Global Biologics for Severe Asthma Revenue by Type (2021–2026)
4.2.2 Global Biologics for Severe Asthma Revenue by Type (2027–2032)
4.2.3 Global Biologics for Severe Asthma Revenue Market Share by Type (2021–2032)
4.3 Global Biologics for Severe Asthma Price by Type (2021–2032)
5 Segment by Application
5.1 Global Biologics for Severe Asthma Sales by Application (2021–2032)
5.1.1 Global Biologics for Severe Asthma Sales by Application (2021–2026)
5.1.2 Global Biologics for Severe Asthma Sales by Application (2027–2032)
5.1.3 Global Biologics for Severe Asthma Sales Market Share by Application (2021–2032)
5.2 Global Biologics for Severe Asthma Revenue by Application (2021–2032)
5.2.1 Global Biologics for Severe Asthma Revenue by Application (2021–2026)
5.2.2 Global Biologics for Severe Asthma Revenue by Application (2027–2032)
5.2.3 Global Biologics for Severe Asthma Revenue Market Share by Application (2021–2032)
5.3 Global Biologics for Severe Asthma Price by Application (2021–2032)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Company Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca Biologics for Severe Asthma Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 AstraZeneca Biologics for Severe Asthma Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Company Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Biologics for Severe Asthma Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Amgen Biologics for Severe Asthma Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 Roche
6.3.1 Roche Company Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche Biologics for Severe Asthma Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Roche Biologics for Severe Asthma Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Company Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Biologics for Severe Asthma Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Novartis Biologics for Severe Asthma Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Sanofi
6.5.1 Sanofi Company Information
6.5.2 Sanofi Description and Business Overview
6.5.3 Sanofi Biologics for Severe Asthma Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Sanofi Biologics for Severe Asthma Product Portfolio
6.5.5 Sanofi Recent Developments/Updates
6.6 Regeneron Pharmaceuticals
6.6.1 Regeneron Pharmaceuticals Company Information
6.6.2 Regeneron Pharmaceuticals Description and Business Overview
6.6.3 Regeneron Pharmaceuticals Biologics for Severe Asthma Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Regeneron Pharmaceuticals Biologics for Severe Asthma Product Portfolio
6.6.5 Regeneron Pharmaceuticals Recent Developments/Updates
6.7 GSK
6.7.1 GSK Company Information
6.7.2 GSK Description and Business Overview
6.7.3 GSK Biologics for Severe Asthma Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 GSK Biologics for Severe Asthma Product Portfolio
6.7.5 GSK Recent Developments/Updates
6.8 Teva Pharmaceuticals
6.8.1 Teva Pharmaceuticals Company Information
6.8.2 Teva Pharmaceuticals Description and Business Overview
6.8.3 Teva Pharmaceuticals Biologics for Severe Asthma Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Teva Pharmaceuticals Biologics for Severe Asthma Product Portfolio
6.8.5 Teva Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Biologics for Severe Asthma Industry Chain Analysis
7.2 Biologics for Severe Asthma Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Biologics for Severe Asthma Production Mode & Process Analysis
7.4 Biologics for Severe Asthma Sales and Marketing
7.4.1 Biologics for Severe Asthma Sales Channels
7.4.2 Biologics for Severe Asthma Distributors
7.5 Biologics for Severe Asthma Customer Analysis
8 Biologics for Severe Asthma Market Dynamics
8.1 Biologics for Severe Asthma Industry Trends
8.2 Biologics for Severe Asthma Market Drivers
8.3 Biologics for Severe Asthma Market Challenges
8.4 Biologics for Severe Asthma Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Biologics for Severe Asthma Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Biologics for Severe Asthma Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Biologics for Severe Asthma Market Competitive Situation by Manufacturers in 2025
Table 4. Global Biologics for Severe Asthma Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Biologics for Severe Asthma Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Biologics for Severe Asthma Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Biologics for Severe Asthma Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Biologics for Severe Asthma Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Biologics for Severe Asthma, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Biologics for Severe Asthma, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Biologics for Severe Asthma, Product Types and Applications
Table 12. Global Key Manufacturers of Biologics for Severe Asthma, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Biologics for Severe Asthma Companies by Tier (Tier 1, Tier 2, Tier 3), based on Biologics for Severe Asthma Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Biologics for Severe Asthma Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Biologics for Severe Asthma Sales by Region (K Units), 2021–2026
Table 18. Global Biologics for Severe Asthma Sales Market Share by Region (2021–2026)
Table 19. Global Biologics for Severe Asthma Sales by Region (K Units), 2027–2032
Table 20. Global Biologics for Severe Asthma Sales Market Share by Region (2027–2032)
Table 21. Global Biologics for Severe Asthma Revenue by Region (US$ Million), 2021–2026
Table 22. Global Biologics for Severe Asthma Revenue Market Share by Region (2021–2026)
Table 23. Global Biologics for Severe Asthma Revenue by Region (US$ Million), 2027–2032
Table 24. Global Biologics for Severe Asthma Revenue Market Share by Region (2027–2032)
Table 25. North America Biologics for Severe Asthma Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Biologics for Severe Asthma Sales by Country (K Units), 2021–2026
Table 27. North America Biologics for Severe Asthma Sales by Country (K Units), 2027–2032
Table 28. North America Biologics for Severe Asthma Revenue by Country (US$ Million), 2021–2026
Table 29. North America Biologics for Severe Asthma Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Biologics for Severe Asthma Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Biologics for Severe Asthma Sales by Country (K Units), 2021–2026
Table 32. Europe Biologics for Severe Asthma Sales by Country (K Units), 2027–2032
Table 33. Europe Biologics for Severe Asthma Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Biologics for Severe Asthma Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Biologics for Severe Asthma Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Biologics for Severe Asthma Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Biologics for Severe Asthma Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Biologics for Severe Asthma Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Biologics for Severe Asthma Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Biologics for Severe Asthma Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Biologics for Severe Asthma Sales by Country (K Units), 2021–2026
Table 42. Latin America Biologics for Severe Asthma Sales by Country (K Units), 2027–2032
Table 43. Latin America Biologics for Severe Asthma Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Biologics for Severe Asthma Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Biologics for Severe Asthma Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Biologics for Severe Asthma Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Biologics for Severe Asthma Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Biologics for Severe Asthma Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Biologics for Severe Asthma Revenue by Country (US$ Million), 2027–2032
Table 50. Global Biologics for Severe Asthma Sales (K Units) by Type (2021–2026)
Table 51. Global Biologics for Severe Asthma Sales (K Units) by Type (2027–2032)
Table 52. Global Biologics for Severe Asthma Sales Market Share by Type (2021–2026)
Table 53. Global Biologics for Severe Asthma Sales Market Share by Type (2027–2032)
Table 54. Global Biologics for Severe Asthma Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Biologics for Severe Asthma Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Biologics for Severe Asthma Revenue Market Share by Type (2021–2026)
Table 57. Global Biologics for Severe Asthma Revenue Market Share by Type (2027–2032)
Table 58. Global Biologics for Severe Asthma Price (US$/Unit) by Type (2021–2026)
Table 59. Global Biologics for Severe Asthma Price (US$/Unit) by Type (2027–2032)
Table 60. Global Biologics for Severe Asthma Sales (K Units) by Application (2021–2026)
Table 61. Global Biologics for Severe Asthma Sales (K Units) by Application (2027–2032)
Table 62. Global Biologics for Severe Asthma Sales Market Share by Application (2021–2026)
Table 63. Global Biologics for Severe Asthma Sales Market Share by Application (2027–2032)
Table 64. Global Biologics for Severe Asthma Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Biologics for Severe Asthma Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Biologics for Severe Asthma Revenue Market Share by Application (2021–2026)
Table 67. Global Biologics for Severe Asthma Revenue Market Share by Application (2027–2032)
Table 68. Global Biologics for Severe Asthma Price (US$/Unit) by Application (2021–2026)
Table 69. Global Biologics for Severe Asthma Price (US$/Unit) by Application (2027–2032)
Table 70. AstraZeneca Company Information
Table 71. AstraZeneca Description and Business Overview
Table 72. AstraZeneca Biologics for Severe Asthma Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. AstraZeneca Biologics for Severe Asthma Product
Table 74. AstraZeneca Recent Developments/Updates
Table 75. Amgen Company Information
Table 76. Amgen Description and Business Overview
Table 77. Amgen Biologics for Severe Asthma Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Amgen Biologics for Severe Asthma Product
Table 79. Amgen Recent Developments/Updates
Table 80. Roche Company Information
Table 81. Roche Description and Business Overview
Table 82. Roche Biologics for Severe Asthma Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Roche Biologics for Severe Asthma Product
Table 84. Roche Recent Developments/Updates
Table 85. Novartis Company Information
Table 86. Novartis Description and Business Overview
Table 87. Novartis Biologics for Severe Asthma Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Novartis Biologics for Severe Asthma Product
Table 89. Novartis Recent Developments/Updates
Table 90. Sanofi Company Information
Table 91. Sanofi Description and Business Overview
Table 92. Sanofi Biologics for Severe Asthma Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Sanofi Biologics for Severe Asthma Product
Table 94. Sanofi Recent Developments/Updates
Table 95. Regeneron Pharmaceuticals Company Information
Table 96. Regeneron Pharmaceuticals Description and Business Overview
Table 97. Regeneron Pharmaceuticals Biologics for Severe Asthma Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Regeneron Pharmaceuticals Biologics for Severe Asthma Product
Table 99. Regeneron Pharmaceuticals Recent Developments/Updates
Table 100. GSK Company Information
Table 101. GSK Description and Business Overview
Table 102. GSK Biologics for Severe Asthma Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. GSK Biologics for Severe Asthma Product
Table 104. GSK Recent Developments/Updates
Table 105. Teva Pharmaceuticals Company Information
Table 106. Teva Pharmaceuticals Description and Business Overview
Table 107. Teva Pharmaceuticals Biologics for Severe Asthma Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Teva Pharmaceuticals Biologics for Severe Asthma Product
Table 109. Teva Pharmaceuticals Recent Developments/Updates
Table 110. Key Raw Materials Lists
Table 111. Raw Materials Key Suppliers Lists
Table 112. Biologics for Severe Asthma Distributors List
Table 113. Biologics for Severe Asthma Customers List
Table 114. Biologics for Severe Asthma Market Trends
Table 115. Biologics for Severe Asthma Market Drivers
Table 116. Biologics for Severe Asthma Market Challenges
Table 117. Biologics for Severe Asthma Market Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
Table 121. Authors List of This Report
List of Figures
Figure 1. Product Picture of Biologics for Severe Asthma
Figure 2. Global Biologics for Severe Asthma Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Biologics for Severe Asthma Market Share by Type: 2025 & 2032
Figure 4. Omalizumab Product Picture
Figure 5. Benralizumab Product Picture
Figure 6. Dupirumab Product Picture
Figure 7. Mepolizumab Product Picture
Figure 8. Reslizumab Product Picture
Figure 9. Tezepelumab-ekko Product Picture
Figure 10. Global Biologics for Severe Asthma Market Value by Application (US$ Million), 2021–2032
Figure 11. Global Biologics for Severe Asthma Market Share by Application: 2025 & 2032
Figure 12. Hospital
Figure 13. Clinic
Figure 14. Other
Figure 15. Global Biologics for Severe Asthma Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 16. Global Biologics for Severe Asthma Market Size (US$ Million), 2021–2032
Figure 17. Global Biologics for Severe Asthma Sales (K Units), 2021–2032
Figure 18. Global Biologics for Severe Asthma Average Price (US$/Unit), 2021–2032
Figure 19. Biologics for Severe Asthma Report Years Considered
Figure 20. Biologics for Severe Asthma Sales Share by Manufacturers in 2025
Figure 21. Global Biologics for Severe Asthma Revenue Share by Manufacturers in 2025
Figure 22. Top 5 and Top 10 Global Biologics for Severe Asthma Players: Market Share by Revenue in Biologics for Severe Asthma in 2025
Figure 23. Biologics for Severe Asthma Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 24. Global Biologics for Severe Asthma Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 25. North America Biologics for Severe Asthma Sales Market Share by Country (2021–2032)
Figure 26. North America Biologics for Severe Asthma Revenue Market Share by Country (2021–2032)
Figure 27. United States Biologics for Severe Asthma Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. Canada Biologics for Severe Asthma Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. Europe Biologics for Severe Asthma Sales Market Share by Country (2021–2032)
Figure 30. Europe Biologics for Severe Asthma Revenue Market Share by Country (2021–2032)
Figure 31. Germany Biologics for Severe Asthma Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. France Biologics for Severe Asthma Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. U.K. Biologics for Severe Asthma Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Italy Biologics for Severe Asthma Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Russia Biologics for Severe Asthma Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Asia Pacific Biologics for Severe Asthma Sales Market Share by Region (2021–2032)
Figure 37. Asia Pacific Biologics for Severe Asthma Revenue Market Share by Region (2021–2032)
Figure 38. China Biologics for Severe Asthma Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Japan Biologics for Severe Asthma Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. South Korea Biologics for Severe Asthma Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. India Biologics for Severe Asthma Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Australia Biologics for Severe Asthma Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. China Taiwan Biologics for Severe Asthma Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Southeast Asia Biologics for Severe Asthma Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Latin America Biologics for Severe Asthma Sales Market Share by Country (2021–2032)
Figure 46. Latin America Biologics for Severe Asthma Revenue Market Share by Country (2021–2032)
Figure 47. Mexico Biologics for Severe Asthma Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Brazil Biologics for Severe Asthma Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Argentina Biologics for Severe Asthma Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Colombia Biologics for Severe Asthma Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Middle East and Africa Biologics for Severe Asthma Sales Market Share by Country (2021–2032)
Figure 52. Middle East and Africa Biologics for Severe Asthma Revenue Market Share by Country (2021–2032)
Figure 53. Turkey Biologics for Severe Asthma Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Saudi Arabia Biologics for Severe Asthma Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. UAE Biologics for Severe Asthma Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Global Sales Market Share of Biologics for Severe Asthma by Type (2021–2032)
Figure 57. Global Revenue Market Share of Biologics for Severe Asthma by Type (2021–2032)
Figure 58. Global Biologics for Severe Asthma Price (US$/Unit) by Type (2021–2032)
Figure 59. Global Sales Market Share of Biologics for Severe Asthma by Application (2021–2032)
Figure 60. Global Revenue Market Share of Biologics for Severe Asthma by Application (2021–2032)
Figure 61. Global Biologics for Severe Asthma Price (US$/Unit) by Application (2021–2032)
Figure 62. Biologics for Severe Asthma Value Chain
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
